Nalaganje...
Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
More than 20 years ago, X-linked severe combined immunodeficiency (SCID-X1) appeared to be the best condition to test the feasibility of hematopoietic stem cell gene therapy. The seminal SCID-X1 clinical studies, based on first-generation gammaretroviral vectors, demonstrated good long-term immune r...
Shranjeno v:
| izdano v: | Hum Gene Ther |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Mary Ann Liebert, Inc.
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4779287/ https://ncbi.nlm.nih.gov/pubmed/26790362 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/hum.2015.137 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|